Background We investigated whether metformin hydrochloride has sustained beneficial
metabolic and (cardio) vascular effects in patients with type 2 diabetes mellitus (DM2) …

Background Metformin is recommended in type 2 diabetes mellitus because it reduced
mortality among overweight participants in the United Kingdom Prospective Diabetes Study …

Aim Metformin therapy reduces microvascular complications in Type 2 diabetes; questions
remain, however, regarding its impact on macrovascular events. This study examined …

Objectives. The UK Prospective Diabetes Study (UKPDS) showed that treatment with
metformin decreases macrovascular morbidity and mortality independent of glycaemic …

Background: The strict limiting criteria for the use of metformin in diabetes mellitus stem
largely from reports, in the 1970s, of mortality and lactic acidosis associated with …

Background. The UKPDS 34 showed that intensive treatment with metformin significantly
reduces macrovascular end‐points and mortality in individuals with newly diagnosed type 2 …

Background: The effects of sulfonylureas and metformin on outcomes of cardiovascular
disease (CVD) in type 2 diabetes are not well-characterized. Objective: To compare the …

OBJECTIVE To investigate the effects of metformin on glycemic control, insulin resistance,
and risk factors for cardiovascular disease in NIDDM subjects from two ethnic groups …

Background: Patients with type 2 diabetes are often obese and require large doses of insulin
to achieve glycemic control. Weight gain often accompanies insulin therapy and results in …

OBJECTIVE The two major classes of antidiabetic drugs, sulfonylureas and metformin, may
differentially affect macrovascular complications and mortality in diabetic patients. We …